Leadership Team

Mr. Lettmann has served as our Chief Executive Officer since September 2023 and as a member of our board of directors since April 2020. He previously served as a member of our board of directors from March 2015 to May 2017. Previously, Mr. Lettmann was a General Partner of Lightstone Ventures from March 2012 to July 2023 and a Partner at Morgenthaler Ventures, a venture capital and private equity firm, since June 2009. He previously served as Chief Executive Officer of Promedior Inc., a biotechnology company acquired by Roche, from January 2019 to February 2020 and as Vice President at Split Rock Partners, a venture capital firm, from June 2006 to June 2009. Mr. Lettmann has been a member of the board of directors of several public and privately held companies, including Ra Pharmaceuticals, a clinical-stage pharmaceutical company acquired by UCB. Mr. Lettmann holds a Bachelor of Arts degree in psychology from the University of Iowa and an MBA from the University of Michigan’s Ross School of Business.

Dr. Alan Sandler has served as our Chief Medical Officer since November 2024, and prior to this had been a member of our board of directors starting August 2024. He also currently serves as a member of the board of directors of Elevation Oncology, Inc., and as a member of the strategic advisory boards of TOLREMO therapeutics AG and N-Power Medicine, as well as the Clinical Advisory Board of Mythic Therapeutics. He served as Executive Vice President and Chief Medical Officer of Mirati Therapeutics, prior to and through its acquisition by Bristol Myers Squibb, from November 2022 to April 2024. Prior to joining Mirati Therapeutics, Dr. Sandler was the President, Head of Global Development, Oncology at Zai Lab Limited from December 2020 to October 2022. Prior to that, Dr. Sandler held roles of increasing responsibility at Genentech, and member of the Roche Group.

Dr. Dillon has served as Chief Business Officer since May 2024. She joined ALX Oncology from Calithera Biosciences, where she most recently served as Senior Vice President of Commercial and Portfolio Strategy. Prior to joining Calithera in 2017, Dr. Dillon served in roles of increasing responsibility across marketing, sales and pipeline commercialization at Genentech. Prior to Genentech, Dr. Dillon was a Senior Consultant at the management consulting firm Campbell Alliance. She completed a postdoctoral fellowship at the University of California, San Francisco, Howard Hughes Medical Institute, in what is now the Broad Stem Cell Center. Dr. Dillon holds a Ph.D. and Master of Science degree in neuroscience from Albert Einstein College of Medicine, and a Bachelor of Arts degree in psychology from the University of Richmond.

Harish Shantharam has served as Chief Financial Officer since January 2025. He joined ALX Oncology from CymaBay Therapeutics, Inc., where he helped guide the company in its transition towards late-stage development and commercial readiness and through its $4.3 billion acquisition by Gilead Sciences, Inc. Earlier in his career, he served in roles of increasing responsibility and scope at Gilead Sciences, including as Vice President and Head of Global Commercial Finance, where he led the financial operations supporting a global $20 to $30 billion-dollar revenue business. Prior to joining Gilead, Mr. Shantharam served in various roles of increasing responsibility driving forecasting, commercial analytics and business development at Amgen. Mr. Shantharam holds an MBA in finance from UCLA Anderson School of Management and a graduate degree in Industrial Engineering from the University of Texas at Arlington. He is also a CFA charter holder.